Telzap, tablets 40 mg 90 pcs

– essential hypertension;

Indications

— essential hypertension;

Pharmacological effect

Pharmacodynamics

Special instructions

Liver dysfunction

Active ingredient

Telmisartan

Composition

Each 40 mg tablet contains:

Pregnancy

Currently, there is no reliable information on the safety of telmisartan in pregnant women. In animal studies, reproductive toxicity of the drug was revealed.

Contraindications

— obstructive diseases of the biliary tract;

Side Effects

According to WHO, adverse effects are classified according to the frequency of their development as follows: very often (≥1/10), often (from ≥1/100 to Within each group, according to the frequency of occurrence, adverse reactions are presented in descending order of severity.

Interaction

Dual blockade of the renin-angiotensin-aldosterone system (RAAS) Concomitant use of telmisartan with aliskiren is contraindicated in patients with diabetes mellitus or renal failure (GFR less than 60 ml/min/1.73 m2 body surface area) and is not recommended in other patients.

Overdose

Symptoms: The most pronounced manifestations of overdose were a marked decrease in blood pressure and tachycardia, and bradycardia, dizziness, increased serum creatinine concentrations and acute renal failure were also reported.

Recommendations for use

The drug is taken orally, 1 time/day, regardless of food intake; The tablets should be taken with liquid. Arterial hypertension The initial recommended dose of Telzap is 40 mg (1 tablet) 1 time / day.

Storage conditions

The drug should be stored out of reach of children at a temperature not exceeding 25°C

Shelf life

2 years

Manufacturer

Sanofi Ilac Sanayi ve Ticaret A.Ş., Türkiye